Hims & Hers Health, Inc. (HIMS)
Hims & Hers Health, Inc. (HIMS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Hims & Hers Health (HIMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hims & Hers: Use This Drop Before It's Too Late
Hims & Hers has experienced a hefty sell-off in recent weeks. This sell-off was mainly caused by short-term turbulence, and I expect the company to resolve these issues in the next quarter. HIMS needs to grow in the mid-teens percentage range for the next few years to justify their current valuation.
Hims & Hers Short Interest Nears All-Time High, Buy The Dip?
Shares of Hims & Hers Health Inc. NYSE: HIMS have been the hottest thing in the medical sector, and for good reason. The company's fundamentals are highly attractive for investors who prefer to acquire growth stories early, before they become too large to price in further expansion.
Hims & Hers: There's Opportunity In This Crash (Upgrade)
Hims & Hers offers a compelling "Buy" opportunity after a 30% pullback, despite recent growth concerns and insider selling. HIMS maintains strong long-term growth targets, aiming for $6.5 billion in revenue and $1.3+ billion in adjusted EBITDA by FY30 (representing ~4x profit expansion from current levels). Current valuation appears more attractive, with HIMS trading at 32.8x EV/FY25 adjusted EBITDA and potentially 24.7x by FY26.
Why Hims & Hers Health, Inc. (HIMS) Dipped More Than Broader Market Today
In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $47.46, marking a -3.85% move from the previous day.
Hims & Hers Advances AI-Powered Personalized Digital Healthcare
HIMS accelerates AI-powered care with new tech leadership, personalized treatments and a major $870 million investment push.
HIMS Stock Declines Despite Launch of New Specialty in Women's Health
Hims & Hers debuts a new women's health specialty, targeting menopause care with personalized treatment plans.
Hims & Hers: Q3 Could Provide Volatility, But The Long-Term Vision Remains Bright
Hims & Hers (HIMS) is emerging as a disruptive force in the obesity treatment market, challenging established GLP-1 drug makers. HIMS has aggressively captured market share, often operating in a legal 'grey area' regarding compounded obesity drugs. Recent FDA policy changes ending temporary compounding allowances raise questions about HIMS's continued ability to offer these treatments.
Here's Why Hims & Hers Health, Inc. (HIMS) Fell More Than Broader Market
Hims & Hers Health, Inc. (HIMS) reached $59.15 at the closing of the latest trading day, reflecting a -5.75% change compared to its last close.
How HIMS Stock Rises To $120?
Hims & Hers stock (NYSE: HIMS) increased by 16% yesterday following its announcement about expanding into the treatment of menopause and perimenopause—a strategic shift indicating that the company is creating revenue sources beyond its debated compounded GLP-1 obesity treatments. With shares already up 150% year-to-date and trading at approximately $60, the critical question now is: could HIMS stock go up another 2x to $120?
Hims & Hers Gains 3.8% in 3 Months: Time to Hold the Stock or Sell?
HIMS expands into men's health and hormones, but rising costs and regulatory hurdles threaten its momentum.
Hims & Hers: Why I'm Betting On HIMS Heading To $100
I see a clear path for Hims & Hers Health to reach $100 a share, and I plan to be there when it gets there. HIMS expects revenue growth to rebound, driven by weight loss and new health offerings, aiming for 30%+ growth in 2026. Despite a temporary dip into negative free cash flow, HIMS maintains strong profitability targets and trades at an attractive 24x forward free cash flow.
